Long-term Longitudinal Imaging of Presynaptic Terminals in PD
Recruiting · NCT06875765 · Interventional (participants receive a specific treatment) · Lead sponsor: Universitaire Ziekenhuizen KU Leuven
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
AIM: To investigate whether SV2A loss spreads from brainstem to cerebral cortex with progression of Parkinson's disease (PD) and to determine whether longitudinal cortical SV2A loss correlates with cognitive decline in PD. STUDY DESIGN: The investigators will re-invite participants (both patients with PD and healthy controls) of a previous longitudinal study (NCT04243304, S61477) to undergo evaluation approximately 7 years after the initial baseline study visit (i.e. on average 10 years since the first motor symptoms). All participants will undergo clinical assessment of motor and non-motor symptoms (including cognitive testing), as well as 11C-UCB-J PET-CT (targeting synaptic density marker SV2A), 18F-FE-PE2I PET-CT (targeting DAT) and brain MRI.
Who can take part
Inclusion criteria
- Participation in study S61477 (NCT04243304)
Exclusion criteria
- Neuropsychiatric diseases (unrelated to PD for PD patients)
- Major internal medical diseases
- History of alcohol or drug abuse
- Relevant abnormalities on MR brain
- Contraindications for MR
- Pregnancy or breastfeeding
- Previous participation in other research studies involving ionizing radiation with \> 1 mSv over past 12 months.
Where it is running
1 location listed.
- UZ Leuven - Leuven, Belgium